Oppenheimer names top SMID software stocks ahead of Q3 earnings

Oppenheimer highlighted Agilysys, Via Transportation, Figma and Intapp ahead of their upcoming quarterly reports, citing demand, sales execution and other potential catalysts while noting company-specific risks. Via has a qualified pipeline exceeding $700 million and Oppenheimer raised its price target using fiscal 2027 estimates, but shekel appreciation and new school deployments may pressure margins and average revenue per customer. Figma’s premium valuation requires sustained outperformance, while Intapp’s upside case is tempered by balanced risk-reward after a significant share-price increase and competition.

Analysis

This is an analyst-preference screen, not a new demand datapoint; immediate upside may be limited if expectations already reflect the setup. The near-term distinction is between operating evidence and narrative: AGYS needs to translate demand and sales-force maturation into bookings and guidance, while VIA’s pipeline matters only if it converts to deployed contracts and revenue without further per-customer dilution. For VIA, shekel strength is a direct margin-offset risk; deployment mix could make revenue growth look healthier than unit economics. Over 1–3 months, profitability evidence and conversion quality matter more than headline pipeline size.

INTA’s likely near-term estimate resilience is not the same as attractive upside after a substantial share-price move. Over 6–18 months, migration-related tailwinds fading raises the bar for Celeste adoption and sales productivity; Salesforce and AI-native vendors are competitive risks, but the article provides no evidence of displacement. FIG has the clearest multiple-duration risk: moderating growth leaves less room for execution merely to meet expectations. Conversely, strong results across FIG or INTA could sustain premium valuations, so avoid treating valuation concern alone as a short signal.

The contrarian point: the roundup’s positive framing may be less informative than the dispersion in proof required. Prefer post-print confirmation over pre-earnings exposure. Reassess if AGYS guidance fails to accelerate, VIA’s profitability inflection or pipeline conversion slips, or INTA’s expansion/Celeste metrics weaken; FIG’s thesis improves if growth reaccelerates enough to support its premium valuation. Verify actual consensus, valuation, and reported operating metrics before sizing positions.

Key Decisions for Investors

• AGYS: Keep on an event watchlist; avoid initiating a full position ahead of the October 26 report. Consider a measured long only if guidance and bookings corroborate demand and the acceleration case. Falsifier: guidance is maintained or cut despite the stated demand backdrop.
• VIA: No pre-print long yet. Track November 9 results for pipeline conversion, customer/revenue impact from school deployments, FX sensitivity, and evidence of the expected profitability inflection. A miss on profitability or worsening per-customer economics invalidates the upside case.
• INTA: Do not chase into the October 27 catalyst after the share-price run. Hold/enter only on evidence of sales productivity and Celeste-driven expansion; reduce exposure if growth relies on fading migration benefits or guidance disappoints. Treat competitive pressure as a monitored risk, not established share loss.
• FIG: Avoid adding ahead of November 4 absent a valuation and expectations check. Premium-multiple exposure is vulnerable to merely in-line growth; revisit after results for evidence of sustained outperformance. Do not short solely on the analyst’s valuation caution.